• HPV distribution was markedly polarised by age in women referred to colposcopy.
Introduction
The prevalence of high-risk human papillomavirus (hrHPV) peaks in young women, with HPV16 being globally the most common type [1, 2] . Approximately 70% of cervical cancers are associated with HPV16 and HPV18, the types targeted by all three prophylactic vaccines [3] [4] [5] [6] . The latest 9-valent vaccine directly also targets five other hrHPVs (HPV31/ 33/45/52/58), and the bivalent vaccine is reported to have moderate to high cross-protective efficacy against a number of other hrHPV types (HPV31/33/35/45/52) [7] [8] [9] [10] [11] . Prophylactic HPV vaccines have high efficacy against high-grade squamous intraepithelial lesions (HSIL), especially in young HPV naïve women [12, 13] . Evidence on protection against invasive cervical cancer from a randomised setting has been reported but long-term efficacy is yet to be confirmed [14] . Comprehensive data of a dramatic decrease in hrHPV infections and HSIL approximately a decade after vaccination are very promising [15] [16] [17] [18] [19] [20] [21] [22] .
Histological HSIL is most prevalent in women in their late twenties or early thirties [23] . The peak incidence of cervical cancer in well-screened populations is among 30-40-year-olds, but remains elevated with advancing age when cervical cancer mortality also increases [24] . An age-specific pattern of hrHPV type distribution with larger proportions of cervical cancer in older women attributed to other hrHPV types than HPV16/18 has been observed, but type distribution in HSIL has conflicting results [25] [26] [27] [28] [29] . At the same time with the initiation of HPV vaccination programs a shift from cytological screening to hrHPV-based screening has taken place [30] [31] [32] , and HPV16/18 genotyping has been advocated as a triage test on the urgency of colposcopy after a positive hrHPV test regardless of age [33] .
Our objective was to study the current age-specific hrHPV type distribution in cervical HSIL lesions in unvaccinated highly screened women. These data are essential in optimizing current and future screening programs.
Material and methods
Women 18 years of age or older referred to Helsinki University Hospital Colposcopy Unit for abnormal cytology between January 2014 and May 2016 were recruited to participate in a prospective cohort study (HELICOPTER study: ISRCTN10933736). The unit is the single referral center in the Helsinki metropolitan area with 4500 annual colposcopies serving a population base of over one million. For this study, we only included women with abnormal cytology without symptoms or clinical pathological findings as the reason of referral. Clinical data was collected at the first colposcopy, and if large loop excision of the transformation zone (LLETZ) was performed based on punch biopsy results, data on that visit was collected as well. All women were examined and treated according to Finnish Current Care guidelines [34] . The protocol was approved by Helsinki University Hospital's Ethical Committee (130/13/03/ 03/2013, 24.4.2013), and written informed consent was acquired from all participants.
Screening and colposcopy
During the study period organised screening was conducted by conventional cervical cytology at five-year intervals. The age of onset and finish of screening varied between municipalities, from 25-30 up to 60-65 years. Opportunistic screening outside the nationwide program was also mainly conducted by conventional cytology. After referral for abnormal cytology colposcopy was performed within time frames set by Finnish Current Care guidelines (Table A. 1) [34] .
A senior colposcopist with national certification or N100 annual colposcopies was always present at colposcopy. In addition to routine samples, endocervical cells were obtained with a brush for HPV genotyping. Decision to treat was mostly based on colposcopically directed punch biopsies. The threshold for treatment was histopathologically confirmed cervical intraepithelial neoplasia grade 2 or worse (CIN2 +). The method of treatment for preinvasive disease was always LLETZ, performed usually within one month of the initial visit. Women referred for cytological HSIL with inadequate colposcopy or suspicion of highgrade lesion at colposcopy were treated with LLETZ at first colposcopy. LLETZ was performed at first visit also for atypical glandular cells, favor neoplasia (AGC-FN).
Clinical data
Clinical data was obtained from the electronic hospital records including a dedicated colposcopy database and histo-and cytopathology reports. Cytology was reported according to the Bethesda system. Histopathological diagnosis was regarded as negative for intraepithelial lesion or malignancy (NILM) when no abnormalities with evidence of HPV were detected. Histopathological low-grade squamous intraepithelial lesion (LSIL) was defined as either HPV atypia/atypia condylomatosa or cervical intraepithelial neoplasia grade 1 (CIN1). Histopathological HSIL was stratified between cervical intraepithelial neoplasia grades 2 and 3 (CIN2 and CIN3). Preinvasive glandular dysplasia was reported as adenocarcinoma in situ (AIS). The most severe histopathological diagnosis from punch biopsies or LLETZ specimen was included in the analysis. The colposcopists, cytologists, and histopathologists were unaware of the HPV genotyping results.
HPV genotyping
The endocervical cells in Sample Transport Medium (STM, Qiagen GMBH, Hilden, Germany) were stored at −20°C and later divided into three aliquots without adding any medium and then stored at −80°C. One aliquot from each sample was sent frozen to Karolinska Institute, Stockholm, Sweden, for genotyping which was performed with the Luminex assay as previously described [35] .
Statistical analyses
The main outcome measures were the age-group specific prevalence of HPV types and their association with cervical histopathological diagnosis. For all analyses the women were divided into three age-strata: b30, 30-44.9, and ≥45 years of age. We grouped the HPV data as follows: For analyses, we grouped histopathological CIN3 and squamous cell carcinoma together as CIN3+, and AIS and invasive adenocarcinoma as AIS+. All high grade cervical histopathological findings were combined as HSIL+ (including CIN2, CIN3, AIS, squamous cell carcinoma and adenocarcinoma). NILM and LSIL were combined as less than HSIL (bHSIL).
We calculated the proportions of different HPV types and HPV groups according to age and histopathological category. We estimated the risk ratios (RR) of being HPV group positive between different age groups according to histopathological findings using binomial logistic regression with the women b30 years of age set as the referent group. All statistical analyses were done with STATA 15 (STATA Corp., College Station, TX).
Results
The study comprised of 1302 women (mean age 37.5) referred for cytological abnormality and HPV typing results were available in 1279 women (Table 1) . For six cases (0.5%) the DNA sample was not taken, and in 17 (1.3%) cases the DNA extraction failed. Of the 23 cases with no HPV typing data available, 16 had histopathological NILM or LSIL, four had CIN2, two had CIN3, and one had invasive cervical cancer (adenocarcinoma). Of the 1279 women 1058 (82.7%) were HPV positive and 221 (17.3%) were HPV negative ( Table 2 ). The vast majority were of Caucasian ancestry and only two were HIV positive.
The most prevalent HPV type was HPV16, found in 362 cases (28.3%). The prevalence of HPV16 decreased with increasing age (Table 2) . Conversely, the proportion of HPV negative cases increased with age, being 32.2% (105/326) in women over 45. Multiple HPV types were found in 340 women (26.6%) and were most common in women b30 years of age. The proportion of HPV16/18 decreased with advancing age irrespective of histopathological findings (Table 2) .
Cervical histopathology results were available for 1261 (98.6%) women ( Table 1 ). The remaining women (n = 18) had normal colposcopy of the cervix and histopathological sampling was not performed. Histopathological HSIL+ was found in 503 (39.3%) cases and lowgrade or normal histopathological findings (bHSIL) in 776 (60.7%) cases.
Association of HPV types with high-grade histology
HPV16/18 positivity increased with increasing severity of histopathological findings, whereas HPV negativity decreased with advancing histopathological grade of squamous lesions (Fig. 1) . The oldest agegroup had the greatest proportions of disease attributed to other hrHPV types than HPV16/18 or HPV negative lesions.
In total 285 of the 503 cases of HSIL+ (56.7%) were associated with HPV16/18, with HPV16 being the most common genotype found in HSIL + in all age-groups (Table 3 , Fig. 1 
Discussion
In this population-based cohort of unvaccinated women referred to colposcopy for abnormal cytology we found distinct age-specific patterns of hrHPV type distribution in high-grade cervical disease. The proportions of HSIL+ attributable to HPV16/18 decreased with increasing age from 64.3% in women under 30 years of age to only 35.1% in women 45 years or above with the group's median age being only 51.4 years. Conversely, other hrHPV types than HPV16/18 were more common in HSIL+ in the oldest age group. Furthermore, approximately 10% of HSIL+ cases in the oldest age group were hrHPV negative.
Previous studies have found comparable age-specific patterns of decreasing HPV16/18 positivity with increasing age in invasive cancer and to a lesser extent in HSIL [25] [26] [27] [28] . Our study is to date the largest population-based study on histopathological HSIL to confirm this agespecific type distribution. The reasons for the observed polarisation of hrHPV types by age remains unclear, but a longer latency to highgrade disease with other types than HPV16/18 has been suggested, as well as the reactivation of latent infections after immune senescence [25, 36] . A birth cohort effect, i.e. women born in a certain calendar time-period having been exposed to different hrHPV types and screened differently, might also play a role. In Finland the overall coverage of organised and opportunistic screening smears (at least one in five years) has, however, been over 90% for decades [37] . However, according to studies on sexual behavior patterns in industrialized countries HPV exposures (new sexual partners) are becoming more common in middle-aged women [38] .
HPV16 and 18 antibody levels have been found to be significantly lower for the quadrivalent vaccine compared to the bivalent vaccine after up to 12 years of follow-up [39] . It is not yet established how long beyond a decade vaccine immune response lasts, or moreover, how permanent the moderate to high cross-protection is. When comparing the hrHPV type distribution assuming total cross-protective efficacy for the bivalent vaccine there were no major differences between the bivalent and 9-valent vaccine-covered HPV types in any histopathological categories by age. However, in light of the confirmed agespecific polarisation of hrHPV type distribution, the incidence of HSIL + might not be reduced to the same extent over time following prophylactic vaccination especially if it relies on cross-protection [12, 13, 20, 21] . These data cannot confirm when the older women have acquired the HPV infections and thus how prophylactic HPV vaccination in adolescence would have altered this. Moreover, larger proportions of highgrade disease were associated with hrHPV types not targeted by the prophylactic vaccines with advancing age (for example 0/57 (0.0%) of cases of CIN3+ in women b30 and 5/38 (13.2%) in women ≥45). When assessing and modelling the efficacy of vaccination with different screening and reflex-testing strategies, the distinct age-specific hrHPV type distribution should not be overlooked. HPV16/18 genotyping has been considered beneficial as an adjunctive triage test, regardless of age [33, 40] . Our findings should be carefully considered when applying HPV16/18 genotyping as a triage test -only approximately a third of HSIL+ in the older women was attributed to these types. Furthermore, in a large retrospective study approximately 20% Number of HPV types of invasive cervical cancers were HPV negative [41] , while 10% HSIL+ lesions in the oldest age group were also hrHPV negative here. These findings should be taken into consideration when shifting to HPVbased screening with the majority of screening-age population still being unvaccinated. Overall approximately 95% of HSIL lesions here were positive for hrHPV types included in most HPV tests approved for screening: up to 96% in women under 30 and 90% in women over 45. Detection of the hrHPV negative lesions would perhaps warrant co-testing with cytology when screening older women who previously have not attended HPV-based screening. This type of strategy has been implemented in Sweden where women approximately 41 years of age are co-tested [42] . However, in women under the age of 30 nearly 90% of CIN3+ and all cases AIS+ were associated with HPV16/18 in comparison to only approximately half of CIN2 cases and a fourth of bHSIL cases. HPV16/18 positivity in this age group can be considered to be strongly associated with true high-grade disease. Screening for all hrHPV types in young women would not, in light of these data, result in detection of significantly more HSIL+, but rather reduce the positive predictive value of the HPV screening test. Stratification of screened HPV types according to age could be hence considered. Strengths of our study are generalisability of findings with the cohort deriving from an unselected population of a single referral center serving a large population base with likely high prior attendance of cytology-based cervical cancer screening. Our data should accurately reflect the current hrHPV type distribution in clinically relevant disease omitting transient infections. HPV status was determined using highquality HPV genotyping in an international HPV reference laboratory, with a very low number of unsuccessful samples. Weaknesses of the study include the small number of cases glandular disease and invasive cancers. The numbers of infections with individual HPV types were also low, excluding HPV16. Our study assessed real-life age-specific HPV type distribution in women requiring colposcopy, not a cross-section of a screening population. Due to this, we were able to include more cases of HSIL+ than studies in screening populations, but the data therefore cannot directly be used to estimate HPV burden in the whole population.
In conclusion, our results showed that HPV type distribution in highgrade cervical lesions is distinctly polarised according to age in a highly screened population with HPV16/18 attributed disease most prevalent in younger women. In women over 45, only a third of the HSIL+ findings were attributable to HPV16/18, while other hrHPV types and hrHPV negativity were more prevalent. The performance of current HPV-based screening is hence age-dependent and could be modified according to age to achieve better predictive values. Furthermore, when the majority of the screening-aged population is still unvaccinated hrHPV test only might not be optimal screening strategy, especially among older women with low prior adherence to screening.
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